Skip to main content
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses

New Research In

Physical Sciences

Featured Portals

  • Physics
  • Chemistry
  • Sustainability Science

Articles by Topic

  • Applied Mathematics
  • Applied Physical Sciences
  • Astronomy
  • Computer Sciences
  • Earth, Atmospheric, and Planetary Sciences
  • Engineering
  • Environmental Sciences
  • Mathematics
  • Statistics

Social Sciences

Featured Portals

  • Anthropology
  • Sustainability Science

Articles by Topic

  • Economic Sciences
  • Environmental Sciences
  • Political Sciences
  • Psychological and Cognitive Sciences
  • Social Sciences

Biological Sciences

Featured Portals

  • Sustainability Science

Articles by Topic

  • Agricultural Sciences
  • Anthropology
  • Applied Biological Sciences
  • Biochemistry
  • Biophysics and Computational Biology
  • Cell Biology
  • Developmental Biology
  • Ecology
  • Environmental Sciences
  • Evolution
  • Genetics
  • Immunology and Inflammation
  • Medical Sciences
  • Microbiology
  • Neuroscience
  • Pharmacology
  • Physiology
  • Plant Biology
  • Population Biology
  • Psychological and Cognitive Sciences
  • Sustainability Science
  • Systems Biology
Research Article

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

Astrid A. Ruefli, Michael J. Ausserlechner, David Bernhard, Vivien R. Sutton, Kellie M. Tainton, Reinhard Kofler, Mark J. Smyth, and Ricky W. Johnstone
PNAS September 11, 2001 98 (19) 10833-10838; https://doi.org/10.1073/pnas.191208598
Astrid A. Ruefli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Ausserlechner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Bernhard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivien R. Sutton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kellie M. Tainton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinhard Kofler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Smyth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricky W. Johnstone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  1. Edited by Paul A. Marks, Memorial Sloan–Kettering Cancer Center, New York, NY, and approved July 11, 2001 (received for review April 27, 2001)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Online Impact

 

Article Information

vol. 98 no. 19 10833-10838
DOI: 
https://doi.org/10.1073/pnas.191208598
PubMed: 
11535817

Published By: 
National Academy of Sciences
Print ISSN: 
0027-8424
Online ISSN: 
1091-6490
History: 
  • Received April 27, 2001
  • Published in issue September 11, 2001.
  • Published first September 4, 2001.

Copyright & Usage: 
Copyright © 2001, The National Academy of Sciences

Author Information

  1. Astrid A. Ruefli*,
  2. Michael J. Ausserlechner,
  3. David Bernhard,
  4. Vivien R. Sutton*,
  5. Kellie M. Tainton*,
  6. Reinhard Kofler,
  7. Mark J. Smyth*, and
  8. Ricky W. Johnstone*‡
  1. *Cancer Immunology Division, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, Saint Andrews Place, East Melbourne, Victoria 3002, Australia; and ‡Tyrolean Cancer Research Institute and Institute for General and Experimental Pathology, University of Innsbruck Medical School, A-6020 Innsbruck, Austria
  1. Edited by Paul A. Marks, Memorial Sloan–Kettering Cancer Center, New York, NY, and approved July 11, 2001 (received for review April 27, 2001)

Footnotes

    • This paper was submitted directly (Track II) to the PNAS office.

    • ‡ To whom reprint requests should be addressed. E-mail: r.johnstone{at}pmci.unimelb.edu.au.

    Cited By...

    • 423 Citations
    • 354 Citations
    • Google Scholar

    This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

    • Anticancer activities of histone deacetylase inhibitors
      Jessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone
      Nature Reviews Drug Discovery 2006 5 9
    • Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
      Ricky W. Johnstone
      Nature Reviews Drug Discovery 2002 1 4
    • Histone deacetylase inhibitors: molecular mechanisms of action
      W S Xu, R B Parmigiani, P A Marks
      Oncogene 2007 26 37
    • Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
      Katrina J. Falkenberg, Ricky W. Johnstone
      Nature Reviews Drug Discovery 2014 13 9
    • Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
      Y. Shao, Z. Gao, P. A. Marks, X. Jiang
      Proceedings of the National Academy of Sciences 2004 101 52
    • Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
      M. J. Peart, G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway, R. W. Johnstone
      Proceedings of the National Academy of Sciences 2005 102 10
    • Histone Deacetylase Inhibitors as Anticancer Drugs
      Tomas Eckschlager, Johana Plch, Marie Stiborova, Jan Hrabeta
      International Journal of Molecular Sciences 2017 18 7
    • Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
      J. S. Ungerstedt, Y. Sowa, W.-S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, P. A. Marks
      Proceedings of the National Academy of Sciences 2005 102 3
    • Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
      Guillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, Alessandra Ferrajoli, Jorge Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary Rosner, Andrey Loboda, Valeria R. Fantin, Sophia S. Randolph, James S. Hardwick, John F. Reilly, Cong Chen, Justin L. Ricker, J. Paul Secrist, Victoria M. Richon, Stanley R. Frankel, Hagop M. Kantarjian
      Blood 2008 111 3
    • Histone deacetylase inhibitors in cancer therapy
      Ricky W Johnstone, Jonathan D Licht
      Cancer Cell 2003 4 1
    • Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
      Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki
      Cancer Letters 2008 269 1
    • Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors
      Xin-Yan Pei, Yun Dai, Steven Grant
      Clinical Cancer Research 2004 10 11
    • A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
      S Balasubramanian, J Ramos, W Luo, M Sirisawad, E Verner, J J Buggy
      Leukemia 2008 22 5
    • Clinical Studies of Histone Deacetylase Inhibitors
      H. Miles Prince, Mark J. Bishton, Simon J. Harrison
      Clinical Cancer Research 2009 15 12
    • Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
      Kapil N. Bhalla
      Journal of Clinical Oncology 2005 23 17
    • Molecular sequelae of histone deacetylase inhibition in human malignant B cells
      Nicholas Mitsiades, Constantine S. Mitsiades, Paul G. Richardson, Ciaran McMullan, Vassiliki Poulaki, Galinos Fanourakis, Robert Schlossman, Dharminder Chauhan, Nikhil C. Munshi, Teru Hideshima, Victoria M. Richon, Paul A. Marks, Kenneth C. Anderson
      Blood 2003 101 10
    • Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
      B H Huang, M Laban, C H-W Leung, L Lee, C K Lee, M Salto-Tellez, G C Raju, S C Hooi
      Cell Death & Differentiation 2005 12 4
    • Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
      J.- H. Lee, M. L. Choy, L. Ngo, S. S. Foster, P. A. Marks
      Proceedings of the National Academy of Sciences 2010 107 33
    • Histone deacetylation in epigenetics: An attractive target for anticancer therapy
      Antonello Mai, Silvio Massa, Dante Rotili, Ilaria Cerbara, Sergio Valente, Riccardo Pezzi, Silvia Simeoni, Rino Ragno
      Medicinal Research Reviews 2005 25 3
    • The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
      Chunrong Yu, Mohamed Rahmani, Daniel Conrad, Mark Subler, Paul Dent, Steven Grant
      Blood 2003 102 10
    • Epigenetics—An Epicenter of Gene Regulation: Histones and Histone-Modifying Enzymes
      Markus Biel, Veit Wascholowski, Athanassios Giannis
      Angewandte Chemie International Edition 2005 44 21
    • The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
      Paul A Marks
      Expert Opinion on Investigational Drugs 2010 19 9
    • Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-κB Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation
      Yun Dai, Mohamed Rahmani, Paul Dent, Steven Grant
      Molecular and Cellular Biology 2005 25 13
    • Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B
      Søren Skov, Marianne Terndrup Pedersen, Lars Andresen, Per Thor Straten, Anders Woetmann, Niels Ødum
      Cancer Research 2005 65 23
    • The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance
      Patricia Maiso, Xonia Carvajal-Vergara, Enrique M. Ocio, Ricardo López-Pérez, Gema Mateo, Norma Gutiérrez, Peter Atadja, Atanasio Pandiella, Jesús F. San Miguel
      Cancer Research 2006 66 11
    • NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
      Laurence Catley, Ellen Weisberg, Yu-Tzu Tai, Peter Atadja, Stacy Remiszewski, Teru Hideshima, Nicholas Mitsiades, Reshma Shringarpure, Richard LeBlanc, Dharminder Chauhan, Nikhil C. Munshi, Robert Schlossman, Paul Richardson, James Griffin, Kenneth C. Anderson
      Blood 2003 102 7
    • Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
      R. K. Lindemann, A. Newbold, K. F. Whitecross, L. A. Cluse, A. J. Frew, L. Ellis, S. Williams, A. P. Wiegmans, A. E. Dear, C. L. Scott, M. Pellegrini, A. Wei, V. M. Richon, P. A. Marks, S. W. Lowe, M. J. Smyth, R. W. Johnstone
      Proceedings of the National Academy of Sciences 2007 104 19
    • BCL-2 in the crosshairs: tipping the balance of life and death
      L D Walensky
      Cell Death & Differentiation 2006 13 8
    • Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
      Milin R. Acharya, Alex Sparreboom, Jürgen Venitz, William D. Figg
      Molecular Pharmacology 2005 68 4
    • Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species
      Mohamed Rahmani, Erin Reese, Yun Dai, Cheryl Bauer, Shawn G. Payne, Paul Dent, Sarah Spiegel, Steven Grant
      Cancer Research 2005 65 6
    • Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus
      Dan P Christensen, Mattias Dahllöf, Morten Lundh, Daniel N Rasmussen, Mette D Nielsen, Nils Billestrup, Lars G Grunnet, Thomas Mandrup-Poulsen
      Molecular Medicine 2011 17 5-6
    • Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
      Fei Guo, Celia Sigua, Jianguo Tao, Purva Bali, Prince George, Yunqing Li, Sylvie Wittmann, Lynn Moscinski, Peter Atadja, Kapil Bhalla
      Cancer Research 2004 64 7
    • Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
      Ailsa J. Frew, Ricky W. Johnstone, Jessica E. Bolden
      Cancer Letters 2009 280 2
    • Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
      Prithviraj Bose, Yun Dai, Steven Grant
      Pharmacology & Therapeutics 2014 143 3
    • Dicer is regulated by cellular stresses and interferons
      Jennifer L. Wiesen, Thomas B. Tomasi
      Molecular Immunology 2009 46 6
    • Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
      W. Xu, L. Ngo, G. Perez, M. Dokmanovic, P. A. Marks
      Proceedings of the National Academy of Sciences 2006 103 42
    • Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
      Daniela Buglio, Georgios V. Georgakis, Shino Hanabuchi, Kazuhiko Arima, Noor M. Khaskhely, Yong-Jun Liu, Anas Younes
      Blood 2008 112 4
    • Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
      S Inoue, M MacFarlane, N Harper, L M C Wheat, M J S Dyer, G M Cohen
      Cell Death & Differentiation 2004 11 S2
    • Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions
      Paul A. Marks
      Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2010 1799 10-12
    • Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)
      Clare Henderson, Michela Mizzau, Gabriela Paroni, Roberta Maestro, Claudio Schneider, Claudio Brancolini
      Journal of Biological Chemistry 2003 278 14
    • Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP protein
      Jennifer L. Aron, Mark R. Parthun, Guido Marcucci, Shinichi Kitada, Andrew P. Mone, Melanie E. Davis, Tiansheng Shen, Timothy Murphy, Joseph Wickham, Chris Kanakry, David M. Lucas, John C. Reed, Michael R. Grever, John C. Byrd
      Blood 2003 102 2
    • TRAIL and cancer therapy
      Frank A.E. Kruyt
      Cancer Letters 2008 263 1
    • Inhibitors of histone deacetylase as antitumor agents: A critical review
      Mohammed Manal, M.J.N. Chandrasekar, Jeyapal Gomathi Priya, M.J. Nanjan
      Bioorganic Chemistry 2016 67
    • Development of vorinostat: Current applications and future perspectives for cancer therapy
      Victoria M. Richon, Jose Garcia-Vargas, James S. Hardwick
      Cancer Letters 2009 280 2
    • Epigenetics and Complex Disease: From Etiology to New Therapeutics
      Carolyn Ptak, Arturas Petronis
      Annual Review of Pharmacology and Toxicology 2008 48 1
    • Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
      Sakura Sakajiri, Takashi Kumagai, Norihiko Kawamata, Takayuki Saitoh, Jonathan W. Said, H. Phillip Koeffler
      Experimental Hematology 2005 33 1
    • Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
      A Quintás-Cardama, F P S Santos, G Garcia-Manero
      Leukemia 2011 25 2
    • The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses
      José Manuel Afonso Moreira, Peter Scheipers, Poul Sørensen
      BMC Cancer 2003 3 1
    • Regulation of cell migration and survival by focal adhesion targeting of Lasp-1
      Yi Hsing Lin, Zee-Yong Park, Dayin Lin, Anar A. Brahmbhatt, Marie-Christine Rio, John R. Yates, Richard L. Klemke
      Journal of Cell Biology 2004 165 3
    • Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives
      Giuseppe Giannini, Walter Cabri, Caterina Fattorusso, Manuela Rodriquez
      Future Medicinal Chemistry 2012 4 11
    • The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells
      Sonia C. Maggio, Roberto R. Rosato, Lora B. Kramer, Yun Dai, Mohamed Rahmani, David S. Paik, Ann C. Czarnik, Shawn G. Payne, Sarah Spiegel, Steven Grant
      Cancer Research 2004 64 7
    • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
      Mikkael A. Sekeres, Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, Rena Buckstein, Min Fang, Diane Roulston, Clara D. Bloomfield, Anna Moseley, Aziz Nazha, Yanming Zhang, Mario R. Velasco, Rakesh Gaur, Ehab Atallah, Eyal C. Attar, Elina K. Cook, Alyssa H. Cull, Michael J. Rauh, Frederick R. Appelbaum, Harry P. Erba
      Journal of Clinical Oncology 2017 35 24
    • Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
      J Almenara, R Rosato, S Grant
      Leukemia 2002 16 7
    • Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
      Satoshi Inoue, Antonello Mai, Martin J.S. Dyer, Gerald M. Cohen
      Cancer Research 2006 66 13
    • Histone deacetylase 1 mRNA expression in lung cancer
      Hidefumi Sasaki, Satoru Moriyama, Yoshiaki Nakashima, Yoshihiro Kobayashi, Masanobu Kiriyama, Ichiro Fukai, Yosuke Yamakawa, Yoshitaka Fujii
      Lung Cancer 2004 46 2
    • Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
      W Yan, S Liu, E Xu, J Zhang, Y Zhang, X Chen, X Chen
      Oncogene 2013 32 5
    • Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
      Michael Dickinson, Ricky W. Johnstone, H. Miles Prince
      Investigational New Drugs 2010 28 S1
    • Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
      S Spiegel, S Milstien, S Grant
      Oncogene 2012 31 5
    • Granzyme M Mediates a Novel Form of Perforin-dependent Cell Death
      Janice M. Kelly, Nigel J. Waterhouse, Erika Cretney, Kylie A. Browne, Sarah Ellis, Joseph A. Trapani, Mark J. Smyth
      Journal of Biological Chemistry 2004 279 21
    • Histone deacetylase inhibitors and cell death
      Jing Zhang, Qing Zhong
      Cellular and Molecular Life Sciences 2014 71 20
    • The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
      D M Lucas, M E Davis, M R Parthun, A P Mone, S Kitada, K D Cunningham, E L Flax, J Wickham, J C Reed, J C Byrd, M R Grever
      Leukemia 2004 18 7
    • An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
      Liqin Wang, Rodrigo Leite de Oliveira, Sanne Huijberts, Evert Bosdriesz, Nora Pencheva, Diede Brunen, Astrid Bosma, Ji-Ying Song, John Zevenhoven, G. Tjitske Los-de Vries, Hugo Horlings, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Rene Bernards
      Cell 2018 173 6
    • Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-κB Activation
      Yasunari Takada, Ann Gillenwater, Haruyo Ichikawa, Bharat B. Aggarwal
      Journal of Biological Chemistry 2006 281 9
    • The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
      Leigh Ellis, Michael Bots, Ralph K. Lindemann, Jessica E. Bolden, Andrea Newbold, Leonie A. Cluse, Clare L. Scott, Andreas Strasser, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone
      Blood 2009 114 2
    • Histone deacetylase inhibitors and genomic instability
      Grégory Eot-Houllier, Géraldine Fulcrand, Laura Magnaghi-Jaulin, Christian Jaulin
      Cancer Letters 2009 274 2
    • Histone deacetylases and epigenetic therapies of hematological malignancies
      Ciro Mercurio, Saverio Minucci, Pier Giuseppe Pelicci
      Pharmacological Research 2010 62 1
    • Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa
      S Inoue, J Riley, T W Gant, M J S Dyer, G M Cohen
      Leukemia 2007 21 8
    • Histone deacetylases as therapeutic targets in hematologic malignancies
      Ari Melnick, Jonathan D. Licht
      Current Opinion in Hematology 2002 9 4
    • p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions
      Hirohito Yamaguchi, Nicholas T. Woods, Landon G. Piluso, Heng-Huan Lee, Jiandong Chen, Kapil N. Bhalla, Alvaro Monteiro, Xuan Liu, Mien-Chie Hung, Hong-Gang Wang
      Journal of Biological Chemistry 2009 284 17
    • The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
      Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, Richard I. Fisher, Jonathan Friedberg, Paul Dent, Steven Grant
      Blood 2010 115 22
    • From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
      Daniel Re, Roman K. Thomas, Karolin Behringer, Volker Diehl
      Blood 2005 105 12
    • Histone deacetylase inhibitors in clinical development
      Roberto R Rosato, Steven Grant
      Expert Opinion on Investigational Drugs 2004 13 1
    • SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib
      S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D’Anneo, P. Di Fazio, R. Vento, G. Tesoriere
      Apoptosis 2007 12 7
    • Redox Control of Leukemia: From Molecular Mechanisms to Therapeutic Opportunities
      Mary E. Irwin, Nilsa Rivera-Del Valle, Joya Chandra
      Antioxidants & Redox Signaling 2013 18 11
    • RETRACTION: The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide
      Roberto R. Rosato, Sonia C. Maggio, Jorge A. Almenara, Shawn G. Payne, Peter Atadja, Sarah Spiegel, Paul Dent, Steven Grant
      Molecular Pharmacology 2006 69 1
    • Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
      Yumin Hu, Weiqin Lu, Gang Chen, Hui Zhang, Yu Jia, Yue Wei, Hui Yang, Wan Zhang, Warren Fiskus, Kapil Bhalla, Michael Keating, Peng Huang, Guillermo Garcia-Manero
      Blood 2010 116 15
    • Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
      Francesca Bruzzese, Monia Rocco, Silvia Castelli, Elena Di Gennaro, Alessandro Desideri, Alfredo Budillon
      Molecular Cancer Therapeutics 2009 8 11
    • Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects
      Wei-Sheng Xu, Gisela Perez, Lang Ngo, Chang-Yun Gui, Paul A. Marks
      Cancer Research 2005 65 17
    • Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
      Luca A. Petruccelli, Daphné Dupéré-Richer, Filippa Pettersson, Hélène Retrouvey, Sophia Skoulikas, Wilson H. Miller, Venugopalan Cheriyath
      PLoS ONE 2011 6 6
    • Histone Deacetylase Inhibitors as Cancer Therapeutics
      Geoffrey M. Matthews, Andrea Newbold, Ricky W. Johnstone
      2012 116
    • Histone deacetylase inhibitors in lymphoma and solid malignancies
      Walid Rasheed, Mark Bishton, Ricky W Johnstone, H Miles Prince
      Expert Review of Anticancer Therapy 2008 8 3
    • Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
      Yanis Boumber, Anas Younes, Guillermo Garcia-Manero
      Expert Opinion on Investigational Drugs 2011 20 6
    • Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
      Roberto R. Rosato, Jorge A. Almenara, Sonia C. Maggio, Stefanie Coe, Peter Atadja, Paul Dent, Steven Grant
      Molecular Cancer Therapeutics 2008 7 10
    • The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
      M. Cecilia Crisanti, Africa F. Wallace, Veena Kapoor, Fabian Vandermeers, Melissa L. Dowling, Luana P. Pereira, Kara Coleman, Barbara G. Campling, Zvi G. Fridlender, Gary D. Kao, Steven M. Albelda
      Molecular Cancer Therapeutics 2009 8 8
    • The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis
      Xu Dong Zhang, Susan K. Gillespie, Jodie M. Borrow, Peter Hersey
      Biochemical Pharmacology 2003 66 8
    • Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies
      Francesco Crea, Stefania Nobili, Elisa Paolicchi, Gabriele Perrone, Cristina Napoli, Ida Landini, Romano Danesi, Enrico Mini
      Drug Resistance Updates 2011 14 6
    • Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
      A. J. Christiansen, A. West, K.-M. Banks, N. M. Haynes, M. W. Teng, M. J. Smyth, R. W. Johnstone
      Proceedings of the National Academy of Sciences 2011 108 10
    • Histone Deacetylase Inhibitors as Cancer Therapeutics
      Carine Robert, Feyruz V. Rassool
      2012 116
    • Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells
      Massimo Donadelli, Chiara Costanzo, Laura Faggioli, Maria Teresa Scupoli, Patrick S. Moore, Claudio Bassi, Aldo Scarpa, Marta Palmieri
      Molecular Carcinogenesis 2003 38 2
    • Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni
      Florence Dubois, Stéphanie Caby, Frédérik Oger, Céline Cosseau, Monique Capron, Christoph Grunau, Colette Dissous, Raymond J. Pierce
      Molecular and Biochemical Parasitology 2009 168 1
    • Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction
      Andrew J. Wilson, Anderly C. Chueh, Lars Tögel, Georgia A. Corner, Naseem Ahmed, Sanjay Goel, Do-Sun Byun, Shannon Nasser, Michele A. Houston, Minaxi Jhawer, Helena J.M. Smartt, Lucas B. Murray, Courtney Nicholas, Barbara G. Heerdt, Diego Arango, Leonard H. Augenlicht, John M. Mariadason
      Cancer Research 2010 70 2
    • Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs
      Kei-ichi Ozaki, Futaba Kishikawa, Masashi Tanaka, Toshiaki Sakamoto, Susumu Tanimura, Michiaki Kohno
      Cancer Science 2008 99 2
    • Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors
      Kate F. Whitecross, Amber E. Alsop, Leonie A. Cluse, Adrian Wiegmans, Kellie-Marie Banks, Claudia Coomans, Melissa J. Peart, Andrea Newbold, Ralph K. Lindemann, Ricky W. Johnstone
      Blood 2009 113 9
    • PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
      Savita Bhalla, Sriram Balasubramanian, Kevin David, Mint Sirisawad, Joseph Buggy, Lauren Mauro, Sheila Prachand, Richard Miller, Leo I. Gordon, Andrew M. Evens
      Clinical Cancer Research 2009 15 10
    • Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
      Olaia Martínez-Iglesias, Lidia Ruiz-Llorente, Ruth Sánchez-Martínez, Laura García, Alberto Zambrano, Ana Aranda
      Clinical and Translational Oncology 2008 10 7
    • Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux
      K M Tainton, M J Smyth, J T Jackson, J E Tanner, L Cerruti, S M Jane, P K Darcy, R W Johnstone
      Cell Death & Differentiation 2004 11 9
    • Dissecting the Biological Functions of Drosophila Histone Deacetylases by RNA Interference and Transcriptional Profiling*
      Cristiana Foglietti, Gessica Filocamo, Enrico Cundari, Emanuele De Rinaldis, Armin Lahm, Riccardo Cortese, Christian Steinkühler
      Journal of Biological Chemistry 2006 281 26
    • Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer
      Constantine S. Mitsiades, Vassiliki Poulaki, Ciaran McMullan, Joseph Negri, Galinos Fanourakis, Athina Goudopoulou, Victoria M. Richon, Paul A. Marks, Nicholas Mitsiades
      Clinical Cancer Research 2005 11 10
    • Emerging therapies for the treatment of relapsed or refractory multiple myeloma
      Meletios A. Dimopoulos, Jesus F. San-Miguel, Kenneth C. Anderson
      European Journal of Haematology 2011 86 1
    • How do tumor cells respond to HDAC inhibition?
      Andrea Newbold, Katrina J. Falkenberg, H. Miles Prince, Ricky W. Johnstone
      The FEBS Journal 2016 283 22
    • Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
      Amit Singh, Anupam Bishayee, Abhay Pandey
      Nutrients 2018 10 6
    • Combined proteasome and histone deacetylase inhibition in non–small cell lung cancer
      Chadrick E Denlinger, Michael D Keller, Marty W Mayo, R.Michael Broad, David R Jones
      The Journal of Thoracic and Cardiovascular Surgery 2004 127 4
    • HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
      Tri Nguyen, Yun Dai, Elisa Attkisson, Lora Kramer, Nicholas Jordan, Nguyen Nguyen, Nikhil Kolluri, Markus Muschen, Steven Grant
      Clinical Cancer Research 2011 17 10
    • Histone deacetylase inhibitors in hematological malignancies and solid tumors
      Pusoon Chun
      Archives of Pharmacal Research 2015 38 6
    • Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines
      Jun Shen, Canhua Huang, Lu Jiang, Feng Gao, Zhi Wang, Yuanyuan Zhang, Jingping Bai, Hongmei Zhou, Qianming Chen
      Biochemical Pharmacology 2007 73 12
    • Histone-Deacetylase-Targeted Fluorescent Ruthenium(II) Polypyridyl Complexes as Potent Anticancer Agents
      Rui-Rong Ye, Zhuo-Feng Ke, Cai-Ping Tan, Liang He, Liang-Nian Ji, Zong-Wan Mao
      Chemistry - A European Journal 2013 19 31
    • Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells
      C Yu, G Dasmahapatra, P Dent, S Grant
      Leukemia 2005 19 9
    • HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
      Matthew J Sweet, Melanie R Shakespear, Nabilah A Kamal, David P Fairlie
      Immunology & Cell Biology 2012 90 1
    • Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer
      Himashinie V.K. Diyabalanage, Michael L. Granda, Jacob M. Hooker
      Cancer Letters 2013 329 1
    • Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death
      Brian K. Rundall, Chadrick E. Denlinger, David R. Jones
      Surgery 2004 136 2
    • Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells
      Ann M. Gillenwater, Meiling Zhong, Reuben Lotan
      Molecular Cancer Therapeutics 2007 6 11
    • Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
      Andrea Newbold, Ralph K. Lindemann, Leonie A. Cluse, Kate F. Whitecross, Anthony E. Dear, Ricky W. Johnstone
      Molecular Cancer Therapeutics 2008 7 5
    • Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells
      Jürgen Sonnemann, Linn Dreyer, Maite Hartwig, Chithra D. Palani, Le Thi Thu Hong, Ulrike Klier, Barbara Bröker, Uwe Völker, James F. Beck
      Journal of Cancer Research and Clinical Oncology 2007 133 11
    • Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
      Luca Paoluzzi, Luigi Scotto, Enrica Marchi, Jasmine Zain, Venkatraman E. Seshan, Owen A. O'Connor
      Clinical Cancer Research 2010 16 2
    • Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway
      Roberto R. Rosato, Sarah S. Kolla, Stefanie K. Hock, Jorge A. Almenara, Ankita Patel, Sanjay Amin, Peter Atadja, Paul B. Fisher, Paul Dent, Steven Grant
      Journal of Biological Chemistry 2010 285 13
    • Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells
      Astrid A. Ruefli, David Bernhard, Kellie M. Tainton, Reinhard Kofler, Mark J. Smyth, Ricky W. Johnstone
      International Journal of Cancer 2002 99 2
    • Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
      Girija Dasmahapatra, Nitin Yerram, Yun Dai, Paul Dent, Steven Grant
      Clinical Cancer Research 2007 13 14
    • Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
      Yukihiko Kato, Brenda C. Salumbides, Xiao-Fei Wang, David Z. Qian, Simon Williams, Yongfeng Wei, Tolib B. Sanni, Peter Atadja, Roberto Pili
      Molecular Cancer Therapeutics 2007 6 1
    • Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe
      M Cornago, C Garcia-Alberich, N Blasco-Angulo, N Vall-llaura, M Nager, J Herreros, J X Comella, D Sanchis, M Llovera
      Cell Death & Disease 2014 5 10
    • Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma
      Clifton Lee Dalgard, Kurtis R. Van Quill, Joan M. O'Brien
      Clinical Cancer Research 2008 14 10
    • Thioredoxin in cancer—Role of histone deacetylase inhibitors
      Paul A. Marks
      Seminars in Cancer Biology 2006 16 6
    • Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
      Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P. Son, Elisa Attkisson, Paul Dent, Richard I. Fisher, Jonathan W. Friedberg, Steven Grant
      Molecular Cancer Therapeutics 2011 10 9
    • Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737
      Adrian P. Wiegmans, Amber E. Alsop, Michael Bots, Leonie A. Cluse, Steven P. Williams, Kellie-Marie Banks, Rachael Ralli, Clare L. Scott, Anna Frenzel, Andreas Villunger, Ricky W. Johnstone
      Cancer Research 2011 71 10
    • Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor–Positive Prostate Cancer Cells
      Oskar W. Rokhlin, Rebecca B. Glover, Natalya V. Guseva, Agshin F. Taghiyev, Karl G. Kohlgraf, Michael B. Cohen
      Molecular Cancer Research 2006 4 2
    • HDAC inhibitors for the treatment of cutaneous T-cell lymphomas
      Sophia Rangwala, Chunlei Zhang, Madeleine Duvic
      Future Medicinal Chemistry 2012 4 4
    • Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
      Jürgen Sonnemann, Jennifer Gänge, Sabine Pilz, Christine Stötzer, Ralf Ohlinger, Antje Belau, Gerd Lorenz, James F Beck
      BMC Cancer 2006 6 1
    • Proteasome inhibition sensitizes non–small cell lung cancer to histone deacetylase inhibitor–induced apoptosis through the generation of reactive oxygen species
      Chadrick E. Denlinger, Brian K. Rundall, David R. Jones
      The Journal of Thoracic and Cardiovascular Surgery 2004 128 5
    • p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
      J Sonnemann, C Marx, S Becker, S Wittig, C D Palani, O H Krämer, J F Beck
      British Journal of Cancer 2014 110 3
    • Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
      R B Erlich, Z Kherrouche, D Rickwood, L Endo-Munoz, S Cameron, A Dahler, M Hazar-Rethinam, L M de Long, K Wooley, A Guminski, N A Saunders
      British Journal of Cancer 2012 106 1
    • Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
      Leigh Ellis, Roberto Pili
      Pharmaceuticals 2010 3 8
    • Deacetylase inhibitors - focus on non-histone targets and effects
      Matthias Ocker
      World Journal of Biological Chemistry 2010 1 5
    • Suberoylanilide Hydroxamic Acid Enhances Gap Junctional Intercellular Communication via Acetylation of Histone Containing Connexin 43 Gene Locus
      Takahiko Ogawa, Tomonori Hayashi, Masahide Tokunou, Kei Nakachi, James E. Trosko, Chia-Cheng Chang, Noriaki Yorioka
      Cancer Research 2005 65 21
    • The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells
      Claudia Campanella, Antonella D'Anneo, Antonella Marino Gammazza, Celeste Caruso Bavisotto, Rosario Barone, Sonia Emanuele, Filippa Lo Cascio, Emanuele Mocciaro, Stefano Fais, Everly Conway De Macario, Alberto J.L. Macario, Francesco Cappello, Marianna Lauricella
      Oncotarget 2016 7 20
    • Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation
      M. Firdos Ziauddin, Wen-Shuz Yeow, Justin B. Maxhimer, Aris Baras, Alex Chua, Rishindra M. Reddy, Wilson Tsai, George W. Cole, David S. Schrump, Dao M. Nguyen
      Neoplasia 2006 8 6
    • A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
      Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael Harb, Leo I. Gordon, Robert Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying Luan, Sharon Horton, Thorsten Graef, Nancy L. Bartlett
      Clinical Cancer Research 2016 22 5
    • Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines
      Pilar García-Morales, Angeles Gómez-Martínez, Alfredo Carrato, Isabel Martínez-Lacaci, Víctor M. Barberá, José L. Soto, Estefanía Carrasco-García, María P. Menéndez-Gutierrez, María D. Castro-Galache, José A. Ferragut, Miguel Saceda
      Molecular Cancer Therapeutics 2005 4 8
    • Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway
      Alessandra Leone, Maria Serena Roca, Chiara Ciardiello, Manuela Terranova-Barberio, Carlo Vitagliano, Gennaro Ciliberto, Rita Mancini, Elena Di Gennaro, Francesca Bruzzese, Alfredo Budillon
      Free Radical Biology and Medicine 2015 89
    • Active extracts of wild fruiting bodies of Antrodia camphorata (EEAC) induce leukemia HL 60 cells apoptosis partially through histone hypoacetylation and synergistically promote anticancer effect of trichostatin A
      Mei-Chin Lu, Ying-Chi Du, Jiunn-Jye Chuu, Shiuh-Lin Hwang, Pao-Chuan Hsieh, Chih-Sheng Hung, Fang-Rong Chang, Yang-Chang Wu
      Archives of Toxicology 2009 83 2
    • Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage
      Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico, Ian F. Pollack
      Molecular Carcinogenesis 2013 52 2
    • The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells
      Ke Long Jin, Jeong-Yeol Park, Eun Joo Noh, Kwang Lae Hoe, Joo Hak Lee, Jong-Hyeok Kim, Joo-Hyun Nam
      Journal of Gynecologic Oncology 2010 21 4
    • Therapy for Latent HIV-1 Infection: The Role of Histone Deacetylase Inhibitors
      Mary E Manson McManamy, Shweta Hakre, Eric M Verdin, David M Margolis
      Antiviral Chemistry and Chemotherapy 2014 23 4
    • Epigenetik - ein Epizentrum der Genregulation: Histone und histonmodifizierende Enzyme
      Markus Biel, Veit Wascholowski, Athanassios Giannis
      Angewandte Chemie 2005 117 21
    • Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
      Claudia P. Miller, Melissa M. Singh, Nilsa Rivera-Del Valle, Christa A. Manton, Joya Chandra
      Journal of Biomedicine and Biotechnology 2011 2011
    • The role of the polycomb complex in silencing α-globin gene expression in nonerythroid cells
      David Garrick, Marco De Gobbi, Vasiliki Samara, Michelle Rugless, Michelle Holland, Helena Ayyub, Karen Lower, Jackie Sloane-Stanley, Nicki Gray, Christoph Koch, Ian Dunham, Douglas R. Higgs
      Blood 2008 112 9
    • Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and aN-(2-Aminophenyl)benzamide Binding Unit
      Charles M. Marson, Christopher J. Matthews, Elena Yiannaki, Stephen J. Atkinson, Peter E. Soden, Lena Shukla, Nermina Lamadema, N. Shaun B. Thomas
      Journal of Medicinal Chemistry 2013 56 15
    • Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib
      Krittaya Sutheesophon, Yukiko Kobayashi, Masa-aki Takatoku, Keiya Ozawa, Yasuhiko Kano, Hideshi Ishii, Yusuke Furukawa
      Acta Haematologica 2006 115 1-2
    • Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
      Andrea Newbold, Geoffrey M. Matthews, Michael Bots, Leonie A. Cluse, Christopher J.P. Clarke, Kellie-Marie Banks, Carleen Cullinane, Jessica E. Bolden, Ailsa J. Christiansen, Ross A. Dickins, Claudia Miccolo, Susanna Chiocca, Astrid M. Kral, Nicole D. Ozerova, Thomas A. Miller, Joey L. Methot, Victoria M. Richon, J. Paul Secrist, Saverio Minucci, Ricky W. Johnstone
      Molecular Cancer Therapeutics 2013 12 12
    • Novel therapeutic agents for cutaneous T-Cell lymphoma
      Salvia Jain, Jasmine Zain, Owen O’Connor
      Journal of Hematology & Oncology 2012 5 1
    • Recent advances in histone deacetylase targeted cancer therapy
      Isamu Hoshino, Hisahiro Matsubara
      Surgery Today 2010 40 9
    • Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy
      Ali R. Jazirehi
      Anti-Cancer Drugs 2010 21 9
    • Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
      Jasmine Zain, Owen A. O’Connor
      Investigational New Drugs 2010 28 S1
    • Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines
      J�rgen Sonnemann, Jennifer G�nge, K. Saravana Kumar, Cornelia M�ller, Peter Bader, James F. Beck
      Investigational New Drugs 2005 23 2
    • Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228)
      Krittaya Sutheesophon, Noriko Nishimura, Yukiko Kobayashi, Yutaka Furukawa, Mikihiko Kawano, Kouichi Itoh, Yasuhiko Kano, Hideshi Ishii, Yusuke Furukawa
      Journal of Cellular Physiology 2005 203 2
    • Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells
      Amel Baya Bouzar, Mathieu Boxus, Julien Defoiche, Guy Berchem, Derek Macallan, Ruth Pettengell, Fenella Willis, Arsène Burny, Laurence Lagneaux, Dominique Bron, Bernard Chatelain, Christian Chatelain, Luc Willems
      British Journal of Haematology 2009 144 1
    • Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death
      Kei-ichi Ozaki, Ai Minoda, Futaba Kishikawa, Michiaki Kohno
      Biochemical and Biophysical Research Communications 2006 339 4
    • Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
      Trine Lillehammer, Birgit O. Engesaeter, Lina Prasmickaite, Gunhild M. Maelandsmo, Oystein Fodstad, Olav Engebraaten
      The Journal of Gene Medicine 2007 9 6
    • Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells
      T Sanda, T Okamoto, Y Uchida, H Nakagawa, S Iida, S Kayukawa, T Suzuki, T Oshizawa, T Suzuki, N Miyata, R Ueda
      Leukemia 2007 21 11
    • Suberoyl Bis‐Hydroxamic Acid Activates Notch‐1 Signaling and Induces Apoptosis in Medullary Thyroid Carcinoma Cells
      Li Ning, David Yu Greenblatt, Muthusamy Kunnimalaiyaan, Herbert Chen
      The Oncologist 2008 13 2
    • Efficacy of vorinostat in a murine model of polycythemia vera
      Hajime Akada, Saeko Akada, Ajeet Gajra, Alicia Bair, Stephen Graziano, Robert E. Hutchison, Golam Mohi
      Blood 2012 119 16
    • Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy
      H.B. Lee, H. Noh, J.Y. Seo, M.R. Yu, H. Ha
      Kidney International 2007 72
    • In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
      Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, Steven Grant
      Molecular Cancer Therapeutics 2014 13 12
    • Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy
      Shuting Xu, Xinyuan Zhu, Wei Huang, Yongfeng Zhou, Deyue Yan
      Journal of Controlled Release 2017 266
    • The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma
      A Newbold, J M Salmon, B P Martin, K Stanley, R W Johnstone
      Oncogene 2014 33 47
    • Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance
      D Dupéré-Richer, M Kinal, V Ménasché, T H Nielsen, S del Rincon, F Pettersson, W H Miller
      Cell Death & Disease 2013 4 2
    • Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities
      Konstantin J. Dedes, Ioannis Dedes, Patrick Imesch, André O. von Bueren, Daniel Fink, André Fedier
      Anti-Cancer Drugs 2009 20 5
    • Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
      Carine Robert, Pratik K. Nagaria, Nisha Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J. Meyers, Philip A. Cole, Feyruz V. Rassool
      Leukemia Research 2016 45
    • Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors
      Maria D. Castro-Galache, Jose A. Ferragut, Victor M. Barbera, Elena Martín-Orozco, Jose M. Gonzalez-Ros, Pilar Garcia-Morales, Miguel Saceda
      International Journal of Cancer 2003 104 5
    • The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
      Eric Sanchez, Jing Shen, Jeffrey Steinberg, Mingjie Li, Cathy Wang, Benjamin Bonavida, Haiming Chen, Zhi-Wei Li, James R. Berenson
      Leukemia Research 2011 35 3
    • Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype
      Clare Henderson, Claudio Brancolini
      Drug Resistance Updates 2003 6 5
    • HDACi
      H.F. Duncan, A.J. Smith, G.J.P. Fleming, P.R. Cooper
      Journal of Dental Research 2011 90 12
    • Histone Deacetylase Inhibitors in Cancer Therapy
      Maryam Fouladi
      Cancer Investigation 2006 24 5
    • Induction of Apoptosis in Renal Tubular Cells by Histone Deacetylase Inhibitors, a Family of Anticancer Agents
      Guie Dong, Lysa Wang, Cong-Yi Wang, Tianxin Yang, M. Vijay Kumar, Zheng Dong
      Journal of Pharmacology and Experimental Therapeutics 2008 325 3
    • LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway
      H Hasegawa, Y Yamada, K Tsukasaki, N Mori, K Tsuruda, D Sasaki, T Usui, A Osaka, S Atogami, C Ishikawa, Y Machijima, S Sawada, T Hayashi, Y Miyazaki, S Kamihira
      Leukemia 2011 25 4
    • RETRACTION: Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2
      Girija Dasmahapatra, Jorge A. Almenara, Steven Grant
      Molecular Pharmacology 2006 69 1
    • Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549)
      Radhakrishnan Vinodhkumar, Young-Sun Song, Vilwanathan Ravikumar, Gopalakrishnan Ramakrishnan, Thiruvengadem Devaki
      Chemico-Biological Interactions 2007 165 3
    • Histone deacetylase inhibitors epigenetically promote reparative events in primary dental pulp cells
      Henry F. Duncan, Anthony J. Smith, Garry J.P. Fleming, Paul R. Cooper
      Experimental Cell Research 2013 319 10
    • Oxidative Stress by Targeted Agents Promotes Cytotoxicity in Hematologic Malignancies
      Joya Chandra
      Antioxidants & Redox Signaling 2009 11 5
    • Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
      Cao Yang, Edwin Choy, Francis J. Hornicek, Kirkham B. Wood, Joseph H. Schwab, Xianzhe Liu, Henry Mankin, Zhenfeng Duan
      Cancer Chemotherapy and Pharmacology 2011 67 2
    • Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells
      Jürgen Sonnemann, Maite Hartwig, Andrea Plath, K. Saravana Kumar, Cornelia Müller, James F. Beck
      Cancer Letters 2006 232 2
    • Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
      F Bruzzese, B Pucci, M R Milone, C Ciardiello, R Franco, M I Chianese, M Rocco, E Di Gennaro, A Leone, A Luciano, C Arra, D Santini, M Caraglia, A Budillon
      Cell Death & Disease 2013 4 10
    • Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and aN-(2-Aminophenyl)-benzamide Binding Unit
      Charles M. Marson, Christopher J. Matthews, Stephen J. Atkinson, Nermina Lamadema, N. Shaun B. Thomas
      Journal of Medicinal Chemistry 2015 58 17
    • Valproic Acid–Induced Gene Expression through Production of Reactive Oxygen Species
      Yumiko Kawai, Ifeanyi J. Arinze
      Cancer Research 2006 66 13
    • Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells
      Nicoletta Fortunati, Silvia Bertino, Lucia Costantino, Ornella Bosco, Ilenia Vercellinatto, Maria Graziella Catalano, Giuseppe Boccuzzi
      Cancer Letters 2008 259 2
    • A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)
      Simon J Harrison, Mark Bishton, Susan E Bates, Steven Grant, Richard L Piekarz, Ricky W Johnstone, Yun Dai, Becki Lee, Maria E Araujo, H Miles Prince
      Epigenomics 2012 4 5
    • Epigenetic therapy of leukemia: An update
      Nitin Jain, Adriana Rossi, Guillermo Garcia-Manero
      The International Journal of Biochemistry & Cell Biology 2009 41 1
    • Exploiting cellular pathways to develop new treatment strategies for AML
      Amir T. Fathi, Steven Grant, Judith E. Karp
      Cancer Treatment Reviews 2010 36 2
    • Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
      W-S Yeow, M F Ziauddin, J B Maxhimer, S Shamimi-Noori, A Baras, A Chua, D S Schrump, D M Nguyen
      British Journal of Cancer 2006 94 10
    • Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia
      Roman Crazzolara, Karin Jöhrer, Ricky W. Johnstone, Richard Greil, Reinhard K Ofler, Bernhard Meister, David Bernhard
      British Journal of Haematology 2002 119 4
    • Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid
      Aiping Tong, Haiyuan Zhang, Zhengyu Li, Lantu Gou, Zhi Wang, Haiyan Wei, Minghai Tang, Shufang Liang, Lijuan Chen, Canhua Huang, Yuquan Wei
      Cancer Chemotherapy and Pharmacology 2008 61 5
    • Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade
      Rishindra M. Reddy, Wen-Shuz Yeow, Alex Chua, Duc M. Nguyen, Aris Baras, M. Firdos Ziauddin, Susan M. Shamimi-Noori, Justin B. Maxhimer, David S. Schrump, Dao M. Nguyen
      Apoptosis 2007 12 1
    • Rhodanese-thioredoxin system and allyl sulfur compounds
      Renato Sabelli, Egidio Iorio, Angelo De Martino, Franca Podo, Alessandro Ricci, Giuditta Viticchiè, Giuseppe Rotilio, Maurizio Paci, Sonia Melino
      FEBS Journal 2008 275 15
    • Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression
      Cheng-Chang Yeh, Yi-Ting Deng, De-Yuan Sha, Michael Hsiao, Mark Yen-Ping Kuo
      Molecular Cancer Therapeutics 2009 8 9
    • Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
      Thomas Prebet, Norbert Vey
      Expert Opinion on Investigational Drugs 2011 20 2
    • Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
      F Lai, S T Guo, L Jin, C C Jiang, C Y Wang, A Croft, M N Chi, H-Y Tseng, M Farrelly, B Atmadibrata, J Norman, T Liu, P Hersey, X D Zhang
      Cell Death & Disease 2013 4 6
    • Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile
      Hisashi Yamada, Yasuhiro Arakawa, Shinobu Saito, Miyuki Agawa, Yasuhiko Kano, Junko Horiguchi-Yamada
      Leukemia Research 2006 30 6
    • Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells
      Ruman Rahman, Teresa Osteso-Ibanez, Robert A. Hirst, Jane Levesley, John-Paul Kilday, Siobhan Quinn, Andrew Peet, Chris O'Callaghan, Beth Coyle, Richard G. Grundy
      Molecular Cancer Therapeutics 2010 9 9
    • Histone Deacetylase Inhibitors as Cancer Therapeutics
      Steven Grant, Yun Dai
      2012 116
    • Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
      G M Matthews, M Lefebure, M A Doyle, J Shortt, J Ellul, M Chesi, K-M Banks, E Vidacs, D Faulkner, P Atadja, P L Bergsagel, R W Johnstone
      Cell Death & Disease 2013 4 9
    • Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress
      Ning Gao, Mohamed Rahmani, Xianglin Shi, Paul Dent, Steven Grant
      Blood 2006 107 1
    • Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy
      Kristy R. Stengel, Scott W. Hiebert
      Antioxidants & Redox Signaling 2015 23 1
    • Emerging role of epigenetic therapies in cutaneous T-cell lymphomas
      Jasmine Zain, David Kaminetzky, Owen A O’Connor
      Expert Review of Hematology 2010 3 2
    • Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side
      Rodrigo Prieto-Bermejo, Marta Romo-González, Alejandro Pérez-Fernández, Carla Ijurko, Ángel Hernández-Hernández
      Journal of Experimental & Clinical Cancer Research 2018 37 1
    • Resveratrol Sensitizes Acute Myelogenous Leukemia Cells to Histone Deacetylase Inhibitors through Reactive Oxygen Species-Mediated Activation of the Extrinsic Apoptotic Pathway
      Alae Yaseen, Shuang Chen, Stefanie Hock, Roberto Rosato, Paul Dent, Yun Dai, Steven Grant
      Molecular Pharmacology 2012 82 6
    • Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide
      Hideki Mizutani, Yusuke Hiraku, Saeko Tada-Oikawa, Mariko Murata, Kenji Ikemura, Takuya Iwamoto, Yoshiyuki Kagawa, Masahiro Okuda, Shosuke Kawanishi
      Cancer Science 2010 101 10
    • Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
      Maria Cosenza, Monica Civallero, Luigi Marcheselli, Stefano Sacchi, Samantha Pozzi
      Apoptosis 2017 22 6
    • The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
      Maria Cosenza, Samantha Pozzi
      International Journal of Molecular Sciences 2018 19 8
    • Trichostatin A Targets the Mitochondrial Respiratory Chain, Increasing Mitochondrial Reactive Oxygen Species Production to Trigger Apoptosis in Human Breast Cancer Cells
      Shujuan Sun, Yingyan Han, Jia Liu, Yong Fang, Yuan Tian, Jianfeng Zhou, Ding Ma, Peng Wu, Dhyan Chandra
      PLoS ONE 2014 9 3
    • 18β-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines
      Chung Soo Lee, Jae Chon Yang, Yun Jeong Kim, Eun-Ra Jang, Wonyong Kim, Soon Chul Myung
      European Journal of Pharmacology 2010 649 1-3
    • Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells
      Eun-Taex Oh, Moon-Taek Park, Bo-Hwa Choi, Seonggu Ro, Eun-Kyung Choi, Seong-Yun Jeong, Heon Joo Park
      Investigational New Drugs 2012 30 2
    • Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
      Roberto R. Rosato, Jorge A. Almenara, Sonia C. Maggio, Peter Atadja, Ruth Craig, Julie Vrana, Paul Dent, Steven Grant
      Molecular Cancer Therapeutics 2005 4 11
    • Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids
      Valérie Lobjois, Céline Frongia, Suzanne Jozan, Isabelle Truchet, Annie Valette
      European Journal of Cancer 2009 45 13
    • Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment
      Canhua Huang, Hiroshi Ida, Kosei Ito, Haiyuan Zhang, Yoshiaki Ito
      Biochemical Pharmacology 2007 73 7
    • DNA Demethylating Agents and Histone Deacetylase Inhibitors in Hematologic Malignancies
      Tamer E. Fandy, Hetty Carraway, Steven D. Gore
      The Cancer Journal 2007 13 1
    • Design and Synthesis of Cyclopeptide Analogues of the Potent Histone Deacetylase Inhibitor FR235222
      Luigi Gomez-Paloma, Ines Bruno, Elena Cini, Saadi Khochbin, Manuela Rodriquez, Maurizio Taddei, Stefania Terracciano, Karin Sadoul
      ChemMedChem 2007 2 10
    • HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines
      Sylwia Flis, Agnieszka Gnyszka, Jacek Spławiński
      Biochemical and Biophysical Research Communications 2009 387 2
    • Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis
      Chuan Bian Lim, Cecilia M. Prêle, Svetlana Baltic, Peter G. Arthur, Jenette Creaney, D. Neil Watkins, Philip J. Thompson, Steven E. Mutsaers
      Oncotarget 2015 6 3
    • Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells
      Aitziber Buqué, Jangi Muhialdin, Alberto Muñoz, Begoña Calvo, Sergio Carrera, Unai Aresti, Aintzane Sancho, Itziar Rubio, Guillermo López-Vivanco
      Molecular Cancer 2012 11 1
    • Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors
      Fei Chen, Hui Chai, Ming-Bo Su, Yang-Ming Zhang, Jia Li, Xin Xie, Fa-Jun Nan
      ACS Medicinal Chemistry Letters 2014 5 6
    • Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species
      Selvaraju Karthik, Renu Sankar, Krishnamoorthy Varunkumar, Chidambaram Anusha, Vilwanathan Ravikumar
      Biomedicine & Pharmacotherapy 2015 69
    • Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
      Noriyuki Takai, Hisashi Narahara
      Obstetrics and Gynecology International 2010 2010
    • Regulation of Oxidative Stress in Pulmonary Artery Endothelium. Modulation of Extracellular Superoxide Dismutase and NOX4 Expression Using Histone Deacetylase Class I Inhibitors
      Igor N. Zelko, Rodney J. Folz
      American Journal of Respiratory Cell and Molecular Biology 2015 53 4
    • Small-molecule chromatin-modifying agents: therapeutic applications
      Antonello Mai
      Epigenomics 2010 2 2
    • Biological activity of dihydroartemisinin in canine osteosarcoma cell lines
      Kenji Hosoya, Sridhar Murahari, Albert Laio, Cheryl A. London, C. Guillermo Couto, William C. Kisseberth
      American Journal of Veterinary Research 2008 69 4
    • PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma
      Giselle Saulnier Sholler, Erika A Currier, Akshita Dutta, Marni A Slavik, Sharon A Illenye, Maria Cecilia F Mendonca, Julie Dragon, Stephen S Roberts, Jeffrey P Bond
      journal of Cancer Therapeutics and Research 2013 2 1
    • Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells
      Laura Bianchi, Francesca Bruzzese, Alessandra Leone, Assunta Gagliardi, Michele Puglia, Elena Di Gennaro, Monia Rocco, Anna Gimigliano, Biagio Pucci, Alessandro Armini, Luca Bini, Alfredo Budillon
      PROTEOMICS 2011 11 18
    • Suberoylanilide Hydroxamic Acid (SAHA)-Induced Dynamics of a Human Histone Deacetylase Protein Interaction Network
      Mihaela E. Sardiu, Karen T. Smith, Brad D. Groppe, Joshua M. Gilmore, Anita Saraf, Rhonda Egidy, Allison Peak, Chris W. Seidel, Laurence Florens, Jerry L. Workman, Michael P. Washburn
      Molecular & Cellular Proteomics 2014 13 11
    • Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells
      Hossein A Hamed, Swadesh K Das, Upneet K Sokhi, Margaret A Park, Nichola Cruickshanks, Kellie Archer, Besim Ogretmen, Steven Grant, Devanand Sarkar, Paul B Fisher, Paul Dent
      Cancer Biology & Therapy 2013 14 11
    • Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression
      Chithra D. Palani, James F. Beck, Jürgen Sonnemann
      Investigational New Drugs 2012 30 1
    • RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells
      Y Zhu, K Das, J Wu, M H Lee, P Tan
      Oncogene 2014 33 12
    • Role ofp53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate
      Jeena Joseph, Narendra Wajapeyee, Kumaravel Somasundaram
      International Journal of Cancer 2005 115 1
    • Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells
      Louisa A. Hooven, Brinda Mahadevan, Channa Keshava, Christopher Johns, Cliff Pereira, Dhimant Desai, Shantu Amin, Ainsley Weston, William M. Baird
      Bioorganic & Medicinal Chemistry Letters 2005 15 5
    • Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
      Maria Mrakovcic, Johannes Kleinheinz, Leopold Fröhlich
      International Journal of Molecular Sciences 2017 18 9
    • Antiproliferative effect of trichostatin a and hc-toxin in T47D Human breast cancer cells
      Ki Eun Joung, Dae-Kee Kim, Yhun Yhong Sheen
      Archives of Pharmacal Research 2004 27 6
    • P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors
      Gianluca Brusa, Elisa Zuffa, Manuela Mancini, Michela Benvenuti, Natalia Calonghi, Enza Barbieri, Maria Alessandra Santucci
      British Journal of Haematology 2006 132 3
    • Stressing the (Epi)Genome: Dealing with Reactive Oxygen Species in Cancer
      Akshay V. Bhat, Shainan Hora, Ananya Pal, Sudhakar Jha, Reshma Taneja
      Antioxidants & Redox Signaling 2018 29 13
    • Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation
      Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
      Scientific Reports 2017 7 1
    • Butyrate-Induced Cell Death and Differentiation Are Associated with Distinct Patterns of ROS in HT29-Derived Human Colon Cancer Cells
      Monika Domokos, Judit Jakus, Krisztina Szeker, Rita Csizinszky, György Csiko, Zsuzsanna Neogrady, Adam Csordas, Peter Galfi
      Digestive Diseases and Sciences 2010 55 4
    • Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
      Maria Mrakovcic, Lauren Bohner, Marcel Hanisch, Leopold F. Fröhlich
      International Journal of Molecular Sciences 2018 19 12
    • Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions
      Bérengère Vire, Stéphane de Walque, Audrey Restouin, Daniel Olive, Carine Van Lint, Yves Collette, Neeraj Vij
      PLoS ONE 2009 4 9
    • Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity
      Thomas W. Hanigan, Shaimaa M. Aboukhatwa, Taha Y. Taha, Jonna Frasor, Pavel A. Petukhov
      Cell Chemical Biology 2017 24 11
    • Histone Deacetylase Inhibitors Interact with Melanoma Differentiation Associated-7/Interleukin-24 to Kill Primary Human Glioblastoma Cells
      Hossein A. Hamed, Adly Yacoub, Margaret A. Park, Kellie Archer, Swadesh K. Das, Devanand Sarkar, Steven Grant, Paul B. Fisher, Paul Dent
      Molecular Pharmacology 2013 84 2
    • Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers
      JING YUAN FANG
      Journal of Gastroenterology and Hepatology 2005 20 7
    • Hydroxamic acids (therapeutics and mechanism): chemistry, acyl nitroso, nitroxyl, reactive oxygen species, and cell signaling
      Peter Kovacic, Corey L. Edwards
      Journal of Receptors and Signal Transduction 2011 31 1
    • MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells
      Sylwia Flis, Agnieszka Gnyszka, Krzysztof Flis, Jacek Spławiński
      European Journal of Pharmacology 2010 627 1-3
    • ROS and RNS induced apoptosis through p53 and iNOS mediated pathway by a dibasic hydroxamic acid molecule in leukemia cells
      Kaushik Banerjee, Avishek Ganguly, Paramita Chakraborty, Avijit Sarkar, Suryabhan Singh, Mitali Chatterjee, Subrato Bhattacharya, Soumitra Kumar Choudhuri
      European Journal of Pharmaceutical Sciences 2014 52
    • Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma
      Jasmine Zain
      Hematology/Oncology Clinics of North America 2012 26 3
    • The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies
      Dao M. Nguyen, Mustafa Hussain
      Journal of Bioenergetics and Biomembranes 2007 39 1
    • Triggering autophagic cell death with a di-manganese(II) developmental therapeutic
      Creina Slator, Zara Molphy, Vickie McKee, Andrew Kellett
      Redox Biology 2017 12
    • p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
      Maria Mrakovcic, Johannes Kleinheinz, Leopold F. Fröhlich
      International Journal of Molecular Sciences 2019 20 10
    • A role for P-glycoprotein in regulating cell growth and survival
      Astrid A Ruefli, Ricky W Johnstone
      Clinical and Applied Immunology Reviews 2003 4 1
    • Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways
      Yi-Jin Chen, Wen-Hung Wang, Wan-Yu Wu, Chia-Chi Hsu, Ling-Rung Wei, Sheng-Fan Wang, Ya-Wen Hsu, Chih-Chuang Liaw, Wan-Chi Tsai, Aamir Ahmad
      PLOS ONE 2017 12 8
    • Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells
      Lubna Wasim, Madhu Chopra
      Biomedicine & Pharmacotherapy 2016 84
    • Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action
      M. S. I. Abaza, A. M. Bahman, R. J. Al-Attiyah, A. M. Kollamparambil
      Tumor Biology 2012 33 6
    • A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways
      Jung Jin Hwang, Yong Sook Kim, Mi Joung Kim, Sejin Jang, Je-Hwan Lee, Jene Choi, Seonggu Ro, Young-Lan Hyun, Jung Shin Lee, Choung-Soo Kim
      Anti-Cancer Drugs 2009 20 9
    • Histone deacetylase inhibitors: clinical implications for hematological malignancies
      Francesco Paolo Tambaro, Carmela Dell’Aversana, Vincenzo Carafa, Angela Nebbioso, Branka Radic, Felicetto Ferrara, Lucia Altucci
      Clinical Epigenetics 2010 1 1-2
    • Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics
      Paul Geeleher, Andrey Loboda, Divya Lenkala, Fan Wang, Bonnie LaCroix, Sanja Karovic, Jacqueline Wang, Michael Nebozhyn, Michael Chisamore, James Hardwick, Michael L. Maitland, R. Stephanie Huang
      Journal of the National Cancer Institute 2015 107 11
    • Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells
      Mati Ur Rehman, Paras Jawaid, Yoko Yoshihisa, Peng Li, Qing Li Zhao, Koichi Narita, Tadashi Katoh, Takashi Kondo, Tadamichi Shimizu
      Chemico-Biological Interactions 2014 221
    • Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells
      Sangkyu Park, Jeong-A Park, Young-Eun Kim, Sukgil Song, Hyung-Joo Kwon, Younghee Lee
      Cell Stress and Chaperones 2015 20 1
    • Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival
      Giorgia Foggetti, Laura Ottaggio, Debora Russo, Carlotta Mazzitelli, Paola Monti, Paolo Degan, Mariangela Miele, Gilberto Fronza, Paola Menichini
      Bioscience Reports 2019 39 2
    • Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors
      Wei Yang, Lixuan Li, Yulan Wang, Xiaowei Wu, Tingting Li, Nan Yang, Mingbo Su, Li Sheng, Mingyue Zheng, Yi Zang, Jia Li, Hong Liu
      Bioorganic & Medicinal Chemistry 2015 23 17
    • Histone deacetylase inhibitors in myelodysplastic syndrome
      K BHALLA, A LIST
      Best Practice & Research Clinical Haematology 2004 17 4
    • Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity
      Brendon Ladd, Jeffrey J. Ackroyd, J. Kevin Hicks, Christine E. Canman, Sheryl A. Flanagan, Donna S. Shewach
      DNA Repair 2013 12 12
    • Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
      Takashi Watanabe
      Expert Opinion on Investigational Drugs 2010 19 9
    • Potent In vivo Anti–Breast Cancer Activity of IN-2001, a Novel Inhibitor of Histone Deacetylase, in MMTV/c-Neu Mice
      Ki E. Joung, Kyung N. Min, Jin Y. An, Dae-Kee Kim, Gu Kong, Y. Yhong Sheen
      Cancer Research 2006 66 10
    • Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf
      Sascha Wagner, Klaus Roemer
      Biochemical Pharmacology 2005 69 7
    • The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors
      Quaovi Sodji, Vishal Patil, Surendra Jain, James R. Kornacki, Milan Mrksich, Babu L. Tekwani, Adegboyega K. Oyelere
      Bioorganic & Medicinal Chemistry Letters 2014 24 20
    • A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells
      Nabanita Patra, Umasankar De, Tae Hyung Kim, Young Ju Lee, Mee Young Ahn, Nam Deuk Kim, Jung Hyun Yoon, Wahn Soo Choi, Hyung Ryong Moon, Byung Mu Lee, Hyung Sik Kim
      Biomedicine & Pharmacotherapy 2013 67 5
    • Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat
      Ben P. Martin, Ailsa J. Frew, Michael Bots, Stephen Fox, Fenella Long, Kazuyoshi Takeda, Hideo Yagita, Peter Atadja, Mark J. Smyth, Ricky W. Johnstone
      International Journal of Cancer 2011 128 11
    • Rationale for Possible Targeting of Histone Deacetylase Signaling in Cancer Diseases with a Special Reference to Pancreatic Cancer
      Mehdi Ouaïssi, Urs Giger, Igor Sielezneff, Nicolas Pirrò, Bernard Sastre, Ali Ouaissi
      Journal of Biomedicine and Biotechnology 2011 2011
    • Aberrant levels of histone H3 acetylation induce spermatid anomaly in mouse testis
      Lei Dai, Daisuke Endo, Naotaro Akiyama, Tomomi Yamamoto-Fukuda, Takehiko Koji
      Histochemistry and Cell Biology 2015 143 2
    • An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts
      M Pinazza, C Borga, V Agnusdei, S Minuzzo, G Fossati, M Paganin, B Michielotto, A De Paoli, G Basso, A Amadori, G te Kronnie, S Indraccolo
      Cell Death & Disease 2016 7 1
    • Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase
      Mi Joung Kim, Jee Suk Lee, Sang Eun Park, Hye-Jin Yi, In Gab Jeong, Jong Soon Kang, Jieun Yun, Joo-Yong Lee, Seonggu Ro, Jung Shin Lee, Eun Kyung Choi, Jung Jin Hwang, Choung-Soo Kim
      Journal of Urology 2015 193 5
    • Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment
      G. Kouraklis, E. P. Misiakos, S. Theocharis
      Targeted Oncology 2006 1 1
    • Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma
      M. Perona, C. Rodríguez, M. Carpano, L. Thomasz, S. Nievas, M. Olivera, S. Thorp, P. Curotto, E. Pozzi, S. Kahl, M. Pisarev, G. Juvenal, A. Dagrosa
      Radiation and Environmental Biophysics 2013 52 3
    • Involvement of caspase activation and mitochondrial stress in trichostatin A-induced apoptosis of Burkitt's lymphoma cell line, Akata
      Young-Ok Son, Ki-Choon Choi, Jeong-Chae Lee, Sung-Ho Kook, Hyun-Jeong Lee, Young-Mi Jeon, Jong-Ghee Kim, Ju Kim, Won-Keun Lee, Yong-Suk Jang
      Journal of Cellular Biochemistry 2006 99 5
    • Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer
      Ferdinando Chiaradonna, Iros Barozzi, Claudia Miccolo, Gabriele Bucci, Roberta Palorini, Lorenzo Fornasari, Oronza A. Botrugno, Giancarlo Pruneri, Michele Masullo, Alfonso Passafaro, Viviana E. Galimberti, Valeria R. Fantin, Victoria M. Richon, Salvatore Pece, Giuseppe Viale, Pier Paolo Di Fiore, Giulio Draetta, Pier Giuseppe Pelicci, Saverio Minucci, Susanna Chiocca
      Antioxidants & Redox Signaling 2015 23 1
    • Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence
      Christopher J. Gregorie, Jennifer L. Wiesen, William J. Magner, Athena W. Lin, Thomas B. Tomasi
      Journal of Reproductive Immunology 2009 81 1
    • The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
      Maria Cosenza, Monica Civallero, Stefania Fiorcari, Samantha Pozzi, Luigi Marcheselli, Alessia Bari, Paola Ferri, Stefano Sacchi
      Cancer Biology & Therapy 2016 17 10
    • Class I HDAC inhibitors enhance YB ‐1 acetylation and oxidative stress to block sarcoma metastasis
      Amal M El‐Naggar, Syam Prakash Somasekharan, Yemin Wang, Hongwei Cheng, Gian Luca Negri, Melvin Pan, Xue Qi Wang, Alberto Delaidelli, Bo Rafn, Jordan Cran, Fan Zhang, Haifeng Zhang, Shane Colborne, Martin Gleave, Anna Mandinova, Nancy Kedersha, Christopher S Hughes, Didier Surdez, Olivier Delattre, Yuzhuo Wang, David G Huntsman, Gregg B Morin, Poul H Sorensen
      EMBO reports 2019 20 12
    • AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair
      Lilach Moyal, Neta Goldfeiz, Batia Gorovitz, Ada Rephaeli, Efrat Tal, Nataly Tarasenko, Abraham Nudelman, Yael Ziv, Emmilia Hodak
      Investigational New Drugs 2018 36 1
    • Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
      Baoyuan Zhang, Junfang Lyu, Eun Ju Yang, Yifan Liu, Changjie Wu, Lakhansing Pardeshi, Kaeling Tan, Qiang Chen, Xiaoling Xu, Chu-Xia Deng, Joong Sup Shim
      Acta Pharmaceutica Sinica B 2020 10 4
    • HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer
      Zhixiong Dong, Yang Yang, Shuxia Liu, Jun Lu, Baiqu Huang, Yu Zhang
      Oncotarget 2018 9 1
    • Histone deacetylase inhibition promotes Caspase-independent cell death of ventral midbrain neurons
      Nicole Forgione, Vincent Tropepe
      Molecular and Cellular Neuroscience 2011 48 2
    • MHC class II regulation by epigenetic agents and microRNAs
      Thomas B. Tomasi, William J. Magner, Jennifer L. Wiesen, Julian Z. Oshlag, Felicia Cao, Alex N. Pontikos, Christopher J. Gregorie
      Immunologic Research 2010 46 1-3
    • MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo
      Ping Ye, Liang Zhao, Crystal McGirr, Thomas J Gonda
      Cancer Letters 2014 343 1
    • The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias
      Joanna Zabkiewicz, Marie Gilmour, Robert Hills, Pares Vyas, Elizabeth Bone, Alan Davidson, Alan Burnett, Steven Knapper
      Oncotarget 2016 7 13
    • A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
      Yoshiaki Ogawa, Michinori Ogura, Kensei Tobinai, Kiyoshi Ando, Tatsuya Suzuki, Takashi Watanabe, Ken Ohmachi, Toshiki Uchida, Mary E. Hanson, Yoshinobu Tanaka, Yasuhiro Koh, Takashi Shimamoto, Tomomitsu Hotta
      International Journal of Hematology 2016 103 1
    • Advances in Targeted Cancer Therapy
      Carlo Palmieri, R. Charles Coombes, David M. Vigushin
      2005 63
    • HDAC inhibitors: applications in oncology and beyond
      Omika Katoch, BS Dwarakanath, Paban K Agrawala
      HOAJ Biology 2013 2 1
    • Pro-apoptotic effect of fly ash leachates in hepatocytes of freshwater fish (Channa punctata Bloch)
      Mehboob Ali, Shakilur Rahman, Hasibur Rehman, Kanchan Bhatia, Rizwan A. Ansari, Sheikh Raisuddin
      Toxicology in Vitro 2007 21 1
    • The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy
      Ana M. Aparicio, Anthony B. Elkhouiery, David I. Quinn
      Urologic Clinics of North America 2005 32 2
    • The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
      S Grant
      Leukemia 2004 18 12
    • Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells
      Jenny Y. Sun, Hsiuyi Tseng, Lian Xu, Zachary Hunter, Bryan Ciccarelli, Mariateresa Fulciniti, Bangmin Zhu, Kaveh Maghsoudi, Guang Yang, Ping Gong, Yangsheng Zhou, Xia Liu, Nikhil C. Munshi, Christopher J. Patterson, Steven P. Treon
      Leukemia & Lymphoma 2011 52 9
    • Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review
      Prabhat Singh, Raghuvir Singh Tomar, Srikanta Kumar Rath
      Molecular Biology Reports 2015 42 11
    • Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines
      Eun-Ra Jang, Yun Jeong Kim, Soon Chul Myung, Wonyong Kim, Chung Soo Lee
      Molecular and Cellular Biochemistry 2011 353 1-2
    • Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
      Umamaheswari Natarajan, Thiagarajan Venkatesan, Vijayaraghavan Radhakrishnan, Shila Samuel, Appu Rathinavelu
      Cells 2018 8 1
    • Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors
      Steven Grant
      Leukemia & Lymphoma 2011 52 9
    • The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells
      Elisabetta Rovida, Antonella Gozzini, Valentina Barbetti, Serena Giuntoli, Valeria Santini, Persio Dello Sbarba
      British Journal of Haematology 2006 135 5
    • Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death
      Barbora Brodska, Petra Otevrelova, Ivan Kalousek
      Cell Biochemistry and Function 2009 27 3
    • A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells
      Sachan Richa, Prasanta Dey, Chaeun Park, Jungho Yang, Ji Yeon Son, Jae Hyeon Park, Su Hyun Lee, Mee-Young Ahn, In Su Kim, Hyung Ryong Moon, Hyung Sik Kim
      Biomolecules & Therapeutics 2020 28 2
    • BimEL-dependent apoptosis induced in peripheral blood lymphocytes withn-butyric acid is moderated by variation in expression of c-myc and p21(WAF1)
      Ivan Kalousek, Barbora Brodska, Petra Otevrelova, Pavla Röselova
      Cell Biochemistry and Function 2008 26 4
    • Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations
      Nilsa Rivera-Del Valle, Tiewei Cheng, Mary E. Irwin, Hayley Donnella, Melissa M. Singh, Joya Chandra
      Cancer Chemotherapy and Pharmacology 2018 81 3
    • Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma
      Syed F Zafar, Ganji Purnachandra Nagaraju, Bassel El-Rayes
      Expert Opinion on Therapeutic Targets 2012 16 7
    • Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor
      Chang-Fang Chiu, Hsien-Kuo Chin, Wei-Jan Huang, Li-Yuan Bai, Hao-Yu Huang, Jing-Ru Weng
      Biomolecules 2019 9 12
    • Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
      Mark J. Bishton, Ricky W. Johnstone, Michael Dickinson, Simon Harrison, H. Miles Prince
      Pharmaceuticals 2010 3 8
    • Targeted Molecular Strategies for Cancer Therapy Based on the Blockade of Oncogenic Pathways in Human Tumor Cells
      Kei-ichi OZAKI
      YAKUGAKU ZASSHI 2007 127 6
    • Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
      Faria Sultana, Kesari Lakshmi Manasa, Siddiq Pasha Shaik, Srinivasa Reddy Bonam, Ahmed Kamal
      Current Medicinal Chemistry 2020 26 40
    • A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
      Tapan M. Kadia, Hui Yang, Alessandra Ferrajoli, Sirisha Maddipotti, Claudia Schroeder, Timothy L. Madden, Julianne L. Holleran, Merrill J. Egorin, Farhad Ravandi, Deborah A. Thomas, Willie Newsome, Blanca Sanchez-Gonzalez, James A. Zwiebel, Igor Espinoza-Delgado, Hagop M. Kantarjian, Guillermo Garcia-Manero
      British Journal of Haematology 2010
    • Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
      Maria Cosenza, Monica Civallero, Luigi Marcheselli, Stefano Sacchi, Samantha Pozzi
      Apoptosis 2020 25 5-6
    • HDAC/HAT Function Assessment and Inhibitor Development
      Lisa Marx-Blümel, Christian Marx, Marie Kühne, Jürgen Sonnemann
      2017 1510
    • N-(2′-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells
      Arturo Contis-Montes de Oca, Estefanía Rodarte-Valle, Martha Cecilia Rosales-Hernández, Edgar Abarca-Rojano, Saúl Rojas-Hernández, Manuel Jonathan Fragoso-Vázquez, Jessica Elena Mendieta-Wejebe, Ana María Correa-Basurto, Ismael Vázquez-Moctezuma, José Correa-Basurto
      Oncotarget 2018 9 70
    • Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent
      Mark A. Miles, Michael A. Harris, Christine J. Hawkins
      Apoptosis 2019 24 5-6
    • SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells
      Jee Suk Lee, Seung Hun Jeong, Young Hwa Soung, Tae Hyun Kim, Hong Jo Choi, Bong Soo Park, Taeg Kyu Kwon, Young Hyun Yoo
      Chemico-Biological Interactions 2009 181 1
    • Tricaproin Isolated From Simarouba glauca Inhibits the Growth of Human Colorectal Carcinoma Cell Lines by Targeting Class-1 Histone Deacetylases
      Asha Jose, Motamari V. N. L. Chaitanya, Elango Kannan, SubbaRao V. Madhunapantula
      Frontiers in Pharmacology 2018 9
    • Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo
      HIROKAZU NAGAI, MASAKO FUJIOKA-KOBAYASHI, GO OHE, KANAE HARA, NATSUMI TAKAMARU, DAISUKE UCHIDA, TETSUYA TAMATANI, KENJI FUJISAWA, YOUJI MIYAMOTO
      Oncology Reports 2014 31 3
    • Cancer Chemoprevention
      Ho Jung Oh, Eun Joo Chung, Sunmin Lee, Andrea Loaiza-Perez, Edward A. Sausville, Jane B. Trepel
      2004
    • Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma
      Aikaterini Mastoraki, Dimitrios Schizas, Nikolaos Charalampakis, Leon Naar, Maria Ioannidi, Diamantis Tsilimigras, Maria Sotiropoulou, Dimitrios Moris, Pantelis Vassiliu, Evangelos Felekouras
      Molecular Diagnosis & Therapy 2020 24 2
    • Epigenetic Therapy in Human Choriocarcinoma
      Noriyuki Takai, Hisashi Narahara
      Cancers 2010 2 3
    • Increased susceptibility to tumor necrosis factor-α in butyric acid-induced apoptosis is caused by downregulation of cFLIP expression in Jurkat T cells
      Shintaro Seto, Tomoko Kurita-Ochiai, Kuniyasu Ochiai
      Microbiology and Immunology 2008 52 3
    • Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
      Maria Mrakovcic, Leopold F. Fröhlich
      Cancers 2019 12 1
    • Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
      Malgorzata Sztiller-Sikorska, Malgorzata Czyz
      Pharmaceuticals 2020 13 8
    • Resistance to Proteasome Inhibitors in Cancer
      Michael Batalo, Prithviraj Bose, Beata Holkova, Steven Grant
      2014
    • Synthesis and biological evaluation of lovastatin-derived aliphatic hydroxamates that induce reactive oxygen species
      Ruo-Kai Lin, Yuh-Feng Lin, Ming-Jen Hsu, Chang-Lin Hsieh, Chen-Yu Wang, Chih-Chiang Huang, Wei-Jan Huang
      Bioorganic & Medicinal Chemistry Letters 2016 26 22
    • T-Cell Lymphomas
      Michael Dickinson, Chan Cheah, H. Miles Prince
      2013
    • Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
      Sangkyu Park, Jeong-A Park, Jae-Hyung Jeon, Younghee Lee
      Biomolecules & Therapeutics 2019 27 5
    • Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms
      Bruno A. Cardoso, Teresa L. Ramos, Hélio Belo, Filipe Vilas-Boas, Carla Real, António M. Almeida
      Experimental Hematology 2019 72
    • Epigenetics of Cancer Prevention
      Shahrzad Movafagh, Amanda Munson
      2019
    • Molecular mechanisms and physiology of disease
      Jane Jisun Sung, Tom C. Karagiannis
      2014
    • Synthesis and Importance of Bulky Aromatic Cap of Novel SAHA Analogs for HDAC Inhibition and Anticancer Activity
      Pu-Soon Chun, Won-Hee Kim, Jung-Su Kim, Jin-Ah Kang, Hye-Jin Lee, Ji-Young Park, Mee-Young Ahn, Hyung-Sik Kim, Hyung-Ryong Moon
      Bulletin of the Korean Chemical Society 2011 32 6
    • The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells
      Kathryn Clarke, Christine Young, Fabio Liberante, Mary-Frances McMullin, Alexander Thompson, Ken Mills
      Oncotarget 2019 10 37
    • The role of a group leader in a surgical research laboratory and his environment – a personal view
      D. Bernhard
      European Surgery 2010 42 3
    • Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma
      Bruna Mascaro-Cordeiro, Indhira Dias Oliveira, Francine Tesser-Gamba, Lorena Favaro Pavon, Nasjla Saba-Silva, Sergio Cavalheiro, Patrícia Dastoli, Silvia Regina Caminada Toledo
      Child's Nervous System 2018 34 8
    • Acute Myelogenous Leukemia
      Tamer Fandy, Hetty Carraway, Steven D. Gore
      2007
    • Acute Promyelocytic Leukemia
      K. Petrie, N. Prodromou, A. Zelent
      2007 313
    • Anti-Cancer Effect of 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide in MCF-7 Human Breast Cancer
      Kyung Nan Min, Ki Eun Joung, Dae-Kee Kim, Yhun Yhong Sheen
      Environmental Health and Toxicology 2012 27
    • Apoptosis in Carcinogenesis and Chemotherapy
      Elizabeth K. Balcer-Kubiczek, Michael C. Garofalo
      2009
    • Application of Apoptosis to Cancer Treatment
      Jiri Neuzill, Ladislav Andera, Brian Gabrielli
      2005
    • Casein kinase 2 inhibition differentially modulates apoptotic effect of trichostatin A against epithelial ovarian carcinoma cell lines
      Chung Soo Lee, Eun-Ra Jang, Yun Jeong Kim, Soon Chul Myung, Wonyong Kim
      Molecular and Cellular Biochemistry 2010 338 1-2
    • Cleavage of HSP90β induced by histone deacetylase inhibitor and proteasome inhibitor modulates cell growth and apoptosis
      Sangkyu Park, Jae-Hyung Jeon, Jeong-A Park, Jun-Kyu Choi, Younghee Lee
      Cell Stress and Chaperones 2021 26 1
    • Effects of Bcl-2 Overexpressing on the Apoptotic Cell Death Induced by HDAC Inhibitors in Human Leukemic U937 Cells
      In-Hyuk Lee, Man-Gyu Hur, Dong-Il Park, Byung-Tae Choi, Yung-Hyun Choi
      Journal of Life Science 2007 17 4
    • Genes and Cancer
      Maria Mrakovcic, Leopold F. Fröhlich
      2019
    • HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
      Carlla Assis Araujo-Silva, Wanderley De Souza, Erica S. Martins-Duarte, Rossiane C. Vommaro
      International Journal for Parasitology: Drugs and Drug Resistance 2021 15
    • Histone Modifications in Therapy
      Vânia Camilo, Carmen Jerónimo
      2020
    • Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
      Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
      Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2019 813
    • Medical Epigenetics
      P. Chun
      2016
    • Molecular Therapies of Cancer
      Georg F. Weber
      2015
    • Pearson's Thoracic and Esophageal Surgery
      Philip W. Smith, David R. Jones
      2008
    • Pharmacoepigenetics
      Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami, Dimitrios Dimitroulis
      2019
    • Polycythemia vera: the current status of preclinical models and therapeutic targets
      Niccolò Bartalucci, Paola Guglielmelli, Alessandro M. Vannucchi
      Expert Opinion on Therapeutic Targets 2020 24 7
    • Prostate Cancer
      Madeleine S. Q. Kortenhorst, Michael A. Carducci, Shabana Shabbeer
      2007
    • Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
      Roberto R. Rosato, Steven Grant
      2008
    • Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
      Fuchun Yang, Shaogang Sun, Chenran Wang, Michael Haas, Syn Yeo, Jun-Lin Guan
      British Journal of Cancer 2020 122 12
    • The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies
      Shiyu Song, Paul Dent, Steven Grant
      2009
    • Tricaproin isolated from Simarouba glauca inhibit colorectal cancer cell growth: A mechanistic approach in vitro and in vivo
      Asha Jose, Kannan Elango, SubbaRao V. Madhunapantula, Achuthan C. Raghavamenon
      Materials Today: Proceedings 2020 33

    Article usage

    Article usage: September 2001 to January 2021

    AbstractFullPdf
    Sep 2001254130401
    Oct 20012173145
    Nov 20018108120
    Dec 2001185650
    Total 2001301367716
    Jan 200226363
    Feb 200255335
    Mar 200264039
    Apr 200224952
    May 200214444
    Jun 2002172421
    Jul 2002113945
    Aug 200272422
    Sep 200222431
    Oct 200233036
    Nov 200223626
    Dec 200212318
    Total 200259449432
    Jan 200372329
    Feb 200343548
    Mar 200302832
    Apr 200342720
    May 200332724
    Jun 200322132
    Jul 200362725
    Aug 2003102251
    Sep 2003272964
    Oct 2003152964
    Nov 2003112964
    Dec 2003192548
    Total 2003108322501
    Jan 2004123743
    Feb 200493047
    Mar 2004155566
    Apr 2004114544
    May 2004224750
    Jun 2004314721
    Jul 200443669
    Aug 2004365528
    Sep 2004183314
    Oct 2004153923
    Nov 2004213632
    Dec 2004252013
    Total 2004258510390
    Jan 2005253327
    Feb 2005113232
    Mar 2005155031
    Apr 200553932
    May 2005111615
    Jun 2005152215
    Jul 2005112921
    Aug 2005153125
    Sep 2005132921
    Oct 2005183019
    Nov 2005204327
    Dec 2005212924
    Total 2005180383289
    Jan 2006153117
    Feb 2006345615
    Mar 2006245721
    Apr 2006172919
    May 2006202626
    Jun 2006172217
    Jul 2006222016
    Aug 2006212410
    Sep 2006242732
    Oct 2006323631
    Nov 2006314945
    Dec 2006183126
    Total 2006275408275
    Jan 2007543843
    Feb 2007172426
    Mar 2007463646
    Apr 2007382421
    May 2007274234
    Jun 2007242322
    Jul 2007232321
    Aug 2007282720
    Sep 2007152025
    Oct 2007402416
    Nov 2007281423
    Dec 200715913
    Total 2007355304310
    Jan 2008232637
    Feb 2008291228
    Mar 2008531742
    Apr 2008271927
    May 2008632432
    Jun 2008201931
    Jul 2008521022
    Aug 2008602022
    Sep 2008642222
    Oct 200842710
    Nov 2008802625
    Dec 2008411511
    Total 2008554217309
    Jan 2009451519
    Feb 2009551517
    Mar 2009201217
    Apr 2009192415
    May 2009552419
    Jun 2009252117
    Jul 2009322722
    Aug 2009313028
    Sep 2009311514
    Oct 2009391315
    Nov 2009321711
    Dec 2009361111
    Total 2009420224205
    Jan 2010381112
    Feb 2010361020
    Mar 2010432126
    Apr 201030713
    May 2010391019
    Jun 2010361215
    Jul 2010391517
    Aug 2010461212
    Sep 2010451613
    Oct 2010392822
    Nov 2010382519
    Dec 2010352211
    Total 2010464189199
    Jan 2011182513
    Feb 201112238
    Mar 2011291112
    Apr 2011291413
    May 2011421728
    Jun 20111898
    Jul 2011292116
    Aug 201124149
    Sep 2011371414
    Oct 2011331916
    Nov 201166189
    Dec 2011421813
    Total 2011379203159
    Jan 2012351716
    Feb 2012592523
    Mar 2012301110
    Apr 2012221712
    May 2012221810
    Jun 2012202412
    Jul 2012231920
    Aug 201222119
    Sep 201221115
    Oct 201223817
    Nov 201220138
    Dec 2012202510
    Total 2012317199152
    Jan 2013292918
    Feb 2013242216
    Mar 2013462416
    Apr 2013231713
    May 2013302112
    Jun 2013372811
    Jul 2013212611
    Aug 2013231512
    Sep 2013171714
    Oct 201322129
    Nov 201319228
    Dec 2013151214
    Total 2013306245154
    Jan 201420914
    Feb 201416228
    Mar 2014222115
    Apr 2014364619
    May 2014331512
    Jun 20141489
    Jul 201428149
    Aug 201430299
    Sep 2014383910
    Oct 2014275811
    Nov 201434339
    Dec 201426305
    Total 2014324324130
    Jan 201519406
    Feb 2015203010
    Mar 201529167
    Apr 2015242413
    May 20152964
    Jun 201516910
    Jul 201516512
    Aug 2015161620
    Sep 201556108
    Oct 201535107
    Nov 201523104
    Dec 201526144
    Total 2015309190105
    Jan 2016391211
    Feb 201622322
    Mar 2016261511
    Apr 201618117
    May 201621511
    Jun 201633156
    Jul 201636127
    Aug 201625813
    Sep 2016331810
    Oct 2016531212
    Nov 20163093
    Dec 201630911
    Total 2016366158104
    Jan 2017311510
    Feb 201728132
    Mar 201732195
    Apr 20172167
    May 20171398
    Jun 20171595
    Jul 201724106
    Aug 2017231411
    Sep 2017181912
    Oct 20173098
    Nov 2017252513
    Dec 20172098
    Total 201728015795
    Jan 2018201513
    Feb 201818198
    Mar 201825269
    Apr 201828317
    May 2018243310
    Jun 2018414215
    Jul 2018353912
    Aug 201851486
    Sep 201822244
    Oct 2018113510
    Nov 2018105331
    Dec 201872914
    Total 2018292394139
    Jan 201952611
    Feb 20195235
    Mar 20197278
    Apr 201954212
    May 201911278
    Jun 20192234
    Jul 201972222
    Aug 201932611
    Sep 201941095
    Oct 2019712817
    Nov 20195136
    Dec 20191206
    Total 201962486115
    Jan 20205266
    Feb 20206218
    Mar 2020712314
    Apr 2020385
    May 20200176
    Jun 2020364
    Jul 20203194
    Aug 202041412
    Sep 20208328
    Oct 2020132011
    Nov 20209219
    Dec 2020162914
    Total 202077336101
    Jan 2021273
    Total 2021273
    Total568860724883
    PreviousNext
    Back to top
    Article Alerts
    Email Article

    Thank you for your interest in spreading the word on PNAS.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
    (Your Name) has sent you a message from PNAS
    (Your Name) thought you would like to see the PNAS web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
    Astrid A. Ruefli, Michael J. Ausserlechner, David Bernhard, Vivien R. Sutton, Kellie M. Tainton, Reinhard Kofler, Mark J. Smyth, Ricky W. Johnstone
    Proceedings of the National Academy of Sciences Sep 2001, 98 (19) 10833-10838; DOI: 10.1073/pnas.191208598

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Request Permissions
    Share
    The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
    Astrid A. Ruefli, Michael J. Ausserlechner, David Bernhard, Vivien R. Sutton, Kellie M. Tainton, Reinhard Kofler, Mark J. Smyth, Ricky W. Johnstone
    Proceedings of the National Academy of Sciences Sep 2001, 98 (19) 10833-10838; DOI: 10.1073/pnas.191208598
    Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Mendeley logo Mendeley
    Proceedings of the National Academy of Sciences: 98 (19)
    Table of Contents

    Submit

    Sign up for Article Alerts

    Jump to section

    • Article
      • Abstract
      • Materials and Methods
      • Results
      • Discussion
      • Acknowledgments
      • Footnotes
      • Abbreviations
      • References
    • Figures & SI
    • Info & Metrics
    • PDF

    You May Also be Interested in

    Abstract depiction of a guitar and musical note
    Science & Culture: At the nexus of music and medicine, some see disease treatments
    Although the evidence is still limited, a growing body of research suggests music may have beneficial effects for diseases such as Parkinson’s.
    Image credit: Shutterstock/agsandrew.
    Large piece of gold
    News Feature: Tracing gold's cosmic origins
    Astronomers thought they’d finally figured out where gold and other heavy elements in the universe came from. In light of recent results, they’re not so sure.
    Image credit: Science Source/Tom McHugh.
    Dancers in red dresses
    Journal Club: Friends appear to share patterns of brain activity
    Researchers are still trying to understand what causes this strong correlation between neural and social networks.
    Image credit: Shutterstock/Yeongsik Im.
    White and blue bird
    Hazards of ozone pollution to birds
    Amanda Rodewald, Ivan Rudik, and Catherine Kling talk about the hazards of ozone pollution to birds.
    Listen
    Past PodcastsSubscribe
    Goats standing in a pin
    Transplantation of sperm-producing stem cells
    CRISPR-Cas9 gene editing can improve the effectiveness of spermatogonial stem cell transplantation in mice and livestock, a study finds.
    Image credit: Jon M. Oatley.

    Similar Articles

    Site Logo
    Powered by HighWire
    • Submit Manuscript
    • Twitter
    • Facebook
    • RSS Feeds
    • Email Alerts

    Articles

    • Current Issue
    • Special Feature Articles – Most Recent
    • List of Issues

    PNAS Portals

    • Anthropology
    • Chemistry
    • Classics
    • Front Matter
    • Physics
    • Sustainability Science
    • Teaching Resources

    Information

    • Authors
    • Editorial Board
    • Reviewers
    • Librarians
    • Press
    • Site Map
    • PNAS Updates

    Feedback    Privacy/Legal

    Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490